Abbott Laboratories: director Kevin T Conroy received 318 shares

What happened Kevin T Conroy, an Abbott Laboratories director, received an award/acquisition of 318 shares (derivative) at $98.83 per share on Sep 30, 2026, valued at $31,428, according to the Form 4.

Key details

• Transaction date and price: Sep 30, 2026 — 318 shares acquired at $98.83 per share; total $31,428.
• Filing date and report period: Form 4 filed Oct 2, 2026; period of report Sep 30, 2026.
• Shares owned after the transaction: not specified in the filing.
• Footnotes from the filing: F1 — director fees are credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board; the stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 — balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
• Late filing: no late filing is indicated in the Form 4.

Why it may matter This was a derivative award under a director grantor trust, not a market purchase or sale. The filing does not show why the insider traded or why the company acted.